首页> 外国专利> FAMILY OF VARIABLE RECOMBINANT HUMAN ANTIBODIES FOR NEUTRALISING THE SCORPION TOXINS CN2 AND CSS2 AND THEIR RESPECTIVE VENOMS: CENTRUROIDES NOXIUS AND CENTRUROIDES SUFFUSUS SUFFUSUS.

FAMILY OF VARIABLE RECOMBINANT HUMAN ANTIBODIES FOR NEUTRALISING THE SCORPION TOXINS CN2 AND CSS2 AND THEIR RESPECTIVE VENOMS: CENTRUROIDES NOXIUS AND CENTRUROIDES SUFFUSUS SUFFUSUS.

机译:用于中毒蝎CN毒素CN2和CSS2及其相应毒液的可变重组人抗体家族:CENTRUROIDES NOXIUS和CENTRUROIDES SUFFUSUS。

摘要

The present invention reveals the method for obtaining a new family of single-chain fragment variable recombinant human antibodies (ScFV). The invention particularly describes a scFv family resulting from independent processes of directed evolution for remarkably improving its binding affinity for the Centruroides noxius Hoffman (Cn2) and Centruroides suffusus suffusus (Css2)toxins, compared to the binding affinity of the parenting antibody, for said toxins. This family presented an improved crossed reactivity against several toxins, particularly neutralising toxins Cn2 and Css2. In addition, each variable neutralising the total venoms of both species, thus being the first antibodies reported with said characteristics. Maturation processes were used to reveal changes in key residues for achieving expression levels, stability and an improved affinity compared to those presented by the parenting scFv. These changes were introduced in the scFv 9004G antibody and the obtained scFv was called, in the present invention, LR, this new variable being able to rescue mice from a severe poisoning caused by 3 LD50 from a total venom fresh preparation of C, noxius (7.5 µ g/ 20 g of mouse) and C. suffusus (26.25µ g/ 20 g of mouse), with success rates of from about 90% and 100%. Finally, the LER variable results from the change in the position 43 in the LR variable. This variable is able to neutralise toxin Cn2 up to a molecular ratio of 1:1. The invention is also related to the DNAs encoding for the members of the new family of scFv, with the molecular vectors that contain said DNAs, with the cells containing these vectors and the methods for producing the antibodies fragment variants, and with pharmaceutical compositions, the use of said antibody fragments for the manufacture of compositions, matrixes that comprise the antibody fragments and diagnosis methods based thereon.
机译:本发明揭示了获得新家族的单链片段可变的重组人抗体(ScFV)的方法。本发明特别描述了由scFv家族,其由定向进化的独立过程产生,与亲本抗体对所述毒素的结合亲和力相比,其显着改善了其对诺森氏霍夫曼毒素(Cn2)和布氏毒素(Css2)毒素的结合亲和力。 。该家族呈现出对几种毒素,特别是中和毒素Cn2和Css2的改善的交叉反应性。另外,每个变量中和两个物种的总毒液,因此是报道具有所述特征的第一抗体。与由亲本scFv呈现的那些相比,成熟过程被用来揭示关键残基的变化以实现表达水平,稳定性和改善的亲和力。将这些变化引入scFv 9004G抗体中,并将​​获得的scFv称为LR,在本发明中,该新变量能够从总的毒液C诺克斯(3,LD50)中拯救小鼠免于3 LD50引起的严重中毒。 7.5 µg / 20 g小鼠)和C. suffusus(26.25µ g / 20 g小鼠),成功率约为90%和100%。最后,LER变量由LR变量中位置43的变化产生。该变量能够中和毒素Cn2直至分子比为1:1。本发明还涉及编码新的scFv家族成员的DNA,含有所述DNA的分子载体,含有这些载体的细胞和产生抗体片段变体的方法,以及涉及药物组合物,其中所述抗体片段在制备组合物,包含抗体片段的基质和基于其的诊断方法中的用途。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号